Search Results

• • 110 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Agonist-bound structure of the human [P2Y.sub.12] receptor

  Authors:Jin Zhang, Kaihua Zhang, Zhan-Guo Gao, Silvia Paoletta, Dandan Zhang, Gye Won Han, et al.From:Nature (Vol. 509, Issue 7498) Peer-Reviewed

  May 1, 20145,077 words Report 1510LThe P2[Y.sub.12] receptor (P2[Y.sub.12]R), one of eight members of the P2YR family expressed in humans, is one of the most prominent clinical drug targets for inhibition of platelet aggregation. Although mutagenesis and...

• Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?

  Authors:Maryna Basalay, Sean Davidson, and Derek YellonFrom:Neural Regeneration Research (Vol. 15, Issue 10) Peer-Reviewed

  Oct. 20202,338 words Article 1610LByline: Maryna. Basalay, Sean. Davidson, Derek. Yellon Currently, ischemic stroke remains one of the most costly and devastating clinical syndromes, accounting for 9% of all deaths and being the second leading cause...

• Increased use of [beta]-agonists leading to non-ST-segment elevation Myocardial infarction in a patient with hemodynamically significant Myocardial bridging

  Authors:Daniel R. Gold, Janet R. Zolli, and Amgad N. MakaryusFrom:Mayo Clinic Proceedings (Vol. 83, Issue 8) Peer-Reviewed

  Aug. 20081,931 words Case study 1490LMyocardial bridging is not uncommon. However, hemodynamic instability in the setting of myocardial bridging is rare. We describe an unusual case of a 47-year-old woman whose increased use of inhaled albuterol led to a...

• 18B Oropharyngeal conditions

  From:MPR Obstetrician & Gynecologist Edition (Vol. 19, Issue 4) Peer-Reviewed

  Winter 2008114 words Brief article EVOXAC Daiichi-Sankyo Rx Cholinergic (muscarinic) agonist. Cevimeline HCl 30mg; caps. Indications: Dry mouth associated with Sjogren's syndrome. Adults: 30mg three times daily. Children: Not recommended....

• Population Pharmacokinetics and Pharmacodynamics of Peptidic Erythropoiesis Receptor Agonist (ERA) in Healthy Volunteers

  Authors:Sukyung Woo, Wojciech Krzyzanski, Anne-Marie Duliege, Richard B. Stead, and William J. JuskoFrom:Journal of Clinical Pharmacology (Vol. 48, Issue 1) Peer-Reviewed

  Jan. 20085,745 words Article 1260LByline: Sukyung Woo, PhD (Department of Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo, New York); Wojciech Krzyzanski, PhD (Department of Pharmaceutical Sciences, State University of New York...

• Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans

  From:Journal of Clinical Pharmacology (Vol. 47, Issue 8) Peer-Reviewed

  Aug. 20074,168 words Clinical report 1530L852A is an imidazoquinoline Toll-like receptor 7 agonist undergoing evaluation for the systemic treatment of cancer. 852A was administered to 6 healthy subjects as 3 rising subcutaneous doses (0.5 to 1.0 to 2.0 mg), to...

• Orchid agonistes

  Author:Misha AngristFrom:Nature (Vol. 465, Issue 7297) Peer-Reviewed

  May 20101,069 words Article 980LThe sweet smell of the past. Author(s): Misha Angrist 1 Author Affiliations: (1) Misha Angrist is at the Duke Institute for Genome Sciences and Policy. His book Here is a Human Being: At the Dawn of Personal...

• Sensory tricks in dystonia: Phenomenology and mechanisms

  Authors:Pooja Mailankody and Pramod PalFrom:Neurology India (Vol. 65, Issue 3) Peer-Reviewed

  May-June 20171,413 words Report 2330LByline: Pooja. Mailankody, Pramod. Pal Dystonia is a hyperkinetic movement disorder characterized by co-contraction of agonists and antagonists resulting in abnormal twisting and repetitive movements or postures, or...

• Long-acting [[beta].sub.2]-agonists may increase risk of severe asthma and death

  Author:Brian S. AlperFrom:Clinical Advisor (Vol. 9, Issue 3)

  Mar. 2006242 words Brief article 1380LLONG-ACTING [[beta].sub.2]-AGONISTS MAY INCREASE RISK OF SEVERE ASTHMA AND DEATH Level 2: Mid-level evidence The FDA recently announced that product labels for long-acting [[beta].sub.2]-agonists (LABAs) will be...

• Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer's disease.

  Authors:Leonardo Brunetti, Antonio Laghezza, Fulvio Loiodice, Paolo Tortorella, and Luca PiemonteseFrom:Neural Regeneration Research (Vol. 15, Issue 1) Peer-Reviewed

  Jan. 20201,754 words Report 1460LByline: Leonardo. Brunetti, Antonio. Laghezza, Fulvio. Loiodice, Paolo. Tortorella, Luca. Piemontese Alzheimer’s disease (AD) is a widespread pathology described for the first time by Aloïs Alzheimer in 1907. It...

• Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells

  Authors:James J. Rough, M Alexandra Monroy, Smitha Yerrum, and John M. DalyFrom:Journal of Ovarian Research (Vol. 3) Peer-Reviewed

  May 26, 20105,492 words Report Background Ovarian cancer is the most common cause of cancer related death from gynecologic tumors in the United States. The insidious nature of the disease precludes early diagnosis, therefore surgical debulking and...

• Regarding the mechanism of action of a proposed peptide agonist of the bone morphogenetic protein receptor activin-like kinase 3

  Authors:Malcolm Whitman, Vicki Rosen, Ali H. Brivanlou, Jay C. Groppe, Walter Sebald, Thomas Mueller, et al.From:Nature Medicine (Vol. 19, Issue 7) Peer-Reviewed

  July 20132,387 words Letter to the editor 1540LTo the Editor: Advances to molecular medicine require not only novel, well-documented observations but also that these observations are placed in the context of the existing molecular understanding of the problem...

• Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.

  Authors:Hilary Siddall, Diana Quint, Hitesh Pandya, Will Powley, Shaila Shabbir, Jens M. Hohlfeld, et al.From:PLoS ONE (Vol. 15, Issue 11) Peer-Reviewed

  Nov. 9, 20206,719 words Report 1460LBackground Allergic asthma is a heterogenous disorder predominantly driven by a type 2 inflammatory response to aeroallergens. Therapeutic modulation to rebalance these type 2 responses may offer clinical benefit for...

• Vasoactive medication dosage and daily weight changes

  Author:Brad CooperFrom:Critical Care Nurse (Vol. 28, Issue 2) Peer-Reviewed

  Apr. 20081,118 words Article 1510LQ Is it appropriate to adjust body surface area and intravenously administered vasoactive medication dosage against daily weight changes in the intensive care unit? Because of these significant changes, is admission...

• Competitive agonists and antagonists of steroid nuclear receptors: evolution of the concept or its reversal

  Author:O.V. SmirnovaFrom:Biochemistry (Moscow) (Vol. 80, Issue 10) Peer-Reviewed

  Oct. 20156,650 words Report 1630LThe mechanisms displaying pure and mixed steroid agonist/antagonist activity as well as principles underlying in vivo action of selective steroid receptor modulators dependent on tissue or cell type including...

• A screen for peptide agonists of the G-CSF receptor

  Authors:Nadine Conzelmann and Armin SchneiderFrom:BMC Research Notes (Vol. 4) Peer-Reviewed

  June 15, 20113,891 words Report 1380LBackground Granulocyte-colony stimulating factor (G-CSF) is one of the most important pharmacologically used proteins. Potential uses beyond the stimulation of neutrophilic granulocytes are the treatment of CNS...

• The structural basis for agonist and partial agonist action on a [[beta].sub.1]-adrenergic receptor

  Authors:Tony Warne, Rouslan Moukhametzianov, Jillian G. Baker, Rony Nehme, Patricia C. Edwards, Andrew G.W. Leslie, et al.From:Nature (Vol. 469, Issue 7329) Peer-Reviewed

  Jan. 13, 20114,526 words Report 1500L[beta]-adrenergic receptors ([beta]ARs) are G-protein-coupled receptors (GPCRs) that activate intracellular G proteins upon binding catecholamine agonist ligands such as adrenaline and noradrenaline (1, 2). Synthetic...

• Stable insulin-secreting ducts formed by reprogramming of cells in the liver using a three-gene cocktail and a PPAR agonist

  Authors:A. Banga, L.V. Greder, J.R. Dutton, and J.M.W. SlackFrom:Gene Therapy (Vol. 21, Issue 1) Peer-Reviewed

  Jan. 20145,953 words Report 1560LWith the long-term aim of developing a new type of therapy for diabetes, we have investigated the reprogramming of liver cells in normal mice toward a pancreatic phenotype using the gene combination Pdx1, Ngn3, MafA....

• Neuroprotective and anti-inflammatory effects of a therapy combining agonists of nicotinic a7 and [sigma]1 receptors in a rat model of Parkinson's disease.

  Authors:Steven Vetel, Laura Foucault-Fruchard, Claire Tronel, FréDéRic Buron, Jackie Vergote, Sylvie Bodard, et al.From:Neural Regeneration Research (Vol. 16, Issue 6) Peer-Reviewed

  June 20215,313 words Report 1490LByline: Steven. Vetel, Laura. Foucault-Fruchard, Claire. Tronel, Frédéric. Buron, Jackie. Vergote, Sylvie. Bodard, Sylvain. Routier, Sophie. Sérrière, Sylvie. Chalon To date there is no treatment able to stop or slow...

• Direct assessment of cumulative aryl hydrocarbon receptor agonist activity in sera from experimentally exposed mice and environmentally exposed humans

  Authors:Jennifer J. Schlezinger, Pamela L. Bernard, Amelia Haas, Philippe Grandjean, Pal Weihe, and David H. SherrFrom:Environmental Health Perspectives (Vol. 118, Issue 5) Peer-Reviewed

  May 20105,728 words Report 1520LBACKGROUND: Aryl hydrocarbon receptor (AhR) ligands adversely affect many biological processes. However, assessment of the significance of human exposures is hampered by an incomplete understanding of how complex...